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Abstract
Background: The sensitivity and selectivity of traditional
methods limits ultramicro detection of proteins. Bio-barcode
amplification detection methods based on nanotechnology
enables ultramicro detection of protein. However, bio-bar-
code amplification detection depends on the oligonucleotides
being fixed on a glass chip. It also requires specialized equip-
ment, which limits its application. We introduce a nano-
nucleic acid barcode dot detection technology to determine
ultramicro concentrations of protein. The method is simple,
quick and accurate.
Methods: Magnetic probe (IgG-M) and dual-labeled gold
nanoparticle bio-probe (IgG-Au-DNA) were prepared. Pro-
tein was captured using a sandwich assay technique and
magnetic separation was used. The DNA barcode was
released with dithiothreitol (DTT) and detected directly with-
out the requirement for polymerase chain reaction (PCR).
Serum prostate-specific antigen (PSA) from 135 patients was
detected with this method and compared with enzyme linked
immunosorbent assay (ELISA) and radioimmuno-
assay (RIA).
Results: Each IgG-Au-DNA could be covered with 138"47
oligonucleotides and 11"3 antibodies. The IgG-M could
bind 118 mg of antibody per mg. The sensitivity of nano-
nucleic acid barcode dot detection technology might allow
detection of 1 fg/mL. There were no significant differences
in serum PSA from 135 patients when comparing the three
methods (compared with ELISA, rs0.950; and with RIA,
rs0.967).
Conclusions: The nucleic acid barcode dot method does not
require special equipment or complex procedures, but its
detection limit is 2–3 orders of magnitude lower than
ELISA.
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Introduction
At present, techniques that use fluorescence labels and
enzyme labels lack adequate sensitivity for early detection
of cancer antigens and some neuropeptides (1–3). Although
the sensitivity of detection using isotopes may reach 1
ng/mL, this requires special equipment and safeguards lim-
iting its application (4).
Polymerase chain reaction (PCR) technology has been
used for the amplification and detection of trace amounts of
DNA (5). This technology can theoretically detect single
stranded DNA and has good specificity (6). However, protein
molecules are different from DNA molecules. The number
of protein molecules cannot be increased using amplification
techniques, which limits sensitivity (1). In 1992, Sano et al.
(7) combined an immunoassay with PCR, creating a high
sensitive detection technology, immuno-PCR. A specific
DNA is attached to antibody using a joining molecule, and
a corresponding relationship is established between antigen
and DNA. Thus, protein detection equates to nucleic acid
detection. However, the oligonucleotide ligation antibody
technique is complex, and the number of oligonucleotides
attached to antibodies is small, limiting sensitivity. In 2003,
Mirkin et al. (8) amplified oligonucleotides on gold nano-
particle bio-probes using PCR. Ultramicro concentration of
protein is measured by detecting the amount of oligonucleo-
tides. However, this method is dependent on oligonucleotides
being fixed on a glass chip requiring special equipment,
which limits its application.
We introduce a method for ultramicro detection of protein
based on nucleic acid barcode dot technology. Hydrosulfo,
biotinylated oligonucleotide (Bio-ssDNA-SH) and rabbit
anti-human prostate-specific antigen (PSA) polyclonal anti-
body were combined with gold nanoparticles (30 nm) to
prepare dual-labeled gold nanoparticle bio-probes (IgG-Au-
DNA) (9). Magnetic micro-spheres are connected with PSA
monoclonal antibodies to produce magnetic probes (IgG-M).
IgG-M reacts with antigens in serum, IgG-Au-DNA is added,
and then the antigen-antibody complex undergoes magnetic
separation. Bio-ssDNA-SH on micro-spheres was diluted
with dithiothreitol (DTT) and coated onto a nitrocellulose
membrane. Bio-ssDNA is detected by the reaction of alkaline
phosphatase-labeled streptavidin (SAAP). Detection of anti-
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Figure 1 Nucleic acid code amplification assay.
(A) Preparation of the dual-labeled gold nanoparticle bio-probes and magnetic probe. (B) PSA detection scheme (DTT, dithiothreitol;
E, enzyme).
gen is performed using nucleic acid barcode detection. Sen-
sitivity to 1 fg/mL may be achieved without use of PCR
(Figure 1). This method was used for the measurement of
serum PSA and compared with enzyme linked immunosor-
bent assay (ELISA) and radioimmunoassay (RIA) methods.
Materials and methods
Preparation of IgG-Au-DNA (9)
Five mL of nano-gold colloid (3.5 nmol/L) was adjusted to pH 9.0
with Na2CO3. Goat antihuman PSA IgG (35 mg) (Lab Vision Cor-
poration, Fremont, USA) and 1000 mL of 39-terminal thiol-modified
oligonucleotide (13.2 mg/mL, Shanghai Sangon Biological Engi-
neering Technology Services Co. Ltd, Shanghai, China) were added
and mixed for 3 h at 48C. Next, 500 mL of phosphate buffered
saline (PBS) (pH 7.4, 0.01 mol/L) and 5 mL of 10% SDS were
added and mixed for 30 min. One mL of NaCl (1.2 mol/L) was
gradually added and allowed to stand for 3 h. Finally, 0.5 mL of
5% bovine serum albumin (BSA) was added and stored in the dark
at 48C.
Preparation of IgG-M
One hundred mg of sodium polymannuronate was dissolved in 4 mL
of purified water and then 2 mL of 5% Fe3O4 magnetic fluid (mean
diameter: 200 nm, The Research Institute of Micro/Nano Science
and Technology, Shanghai Jiao Tong University, Shanghai, China)
was added and mixed at 428C followed by ultrasound for 15 min.
The mixture was adjusted to pH 10.0 with 10% Na2CO3, and heated
to 608C. Using ultrasound and high speed stirring, the mixture was
added to 90 mL of AOT/normal heptane oil at 608C forming a
transparent gray-black reverse microemulsion system. Using ultra-
sound and stirring, 4.5 mL of 30% CaCl2 was added to the micro-
emulsion, followed by magnetic separation, and then washing with
acetone, alcohol and distilled water, respectively. Following centri-
fugation and vacuum freeze-drying, the resultant material was
stored.
One mg of prepared magnetic spheres was removed, washed three
times with phosphate buffer, and then 0.01 mol/L PBS (pH 7.0) was
added to produce a final volume of 4 mL. Five mg of water soluble
carbodiimide (EDC) and 7.5 mg of sufl-NHS were added and mixed
for 15 min at room temperature. Next, 50 mg of 6-aminocaproic
acid was added and stirred for 3 h. We then added 600 mL of PSA
monoclonal antibodies (30 mg/mL; Lab Vision Corporation, USA)
followed by stirring for 6 h, then sealed with 1 mL of glycine
solution (0.2 M) containing 0.2% BSA, and finally magnetic sepa-
ration before storing at 48C. The shape was observed with a trans-
mission electron microscope (TEM) and light microscope.
Nucleic acid barcode dot detection method
Forty mL of magnetic spheres (5 mg/mL), and 20 mL of PSA stan-
dard solution was prepared by diluting 13 mg of the PSA standard
with PBS (pH 7.2) containing 0.2% BSA in a 1 mL volume at
10 mg/mL, 1 mg/mL, 100 ng/mL, 1 ng/mL, 10 pg/mL, 100 fg/mL
or 1 fg/mL, or 20 mL of test serum diluted with PBS (pH 7.2)
containing 0.2% BSA to 1:50. These were incubated at 378C for
1 h followed by magnetic separation, then washed three times with
0.01 mol/L PBS (pH 7.4) containing 0.2% BSA, and then 80 mL
of gold nanoparticle probes (10 nmol/L) was added at 378C for 1 h
followed by magnetic separation, then washed three times with
0.01 mol/L PBS (pH 7.4) containing 0.2% BSA. To a volume of
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Figure 2 Immunoreactive antibodies in magnetic probes analyzed
by flow cytometry.
Figure 3 Standard curve for PSA analysis.
50 mL, 5 mL of DTT (Sigma Company, St. Louis, USA) was added
to make the final concentration be 0.01 mol/L, DNA was dissociated
for 3 h followed by magnetic separation and ultracentrifugation at
8944 g for 5 min at low temperature. Next, 10 mL of separated
DNA barcode was coated on a 5=8 cm nylon membrane and baked
at 608C for 30 min. SAAP (dilution 1:100; Lab Vision Corporation,
USA) was then added and 30 min after reaction at room tempera-
ture, washed with 0.01 mol/L PBS (pH 7.4) three times. This was
followed by addition of NBT/BCIP (nitroblue tetrazolium/5-bromo-
chloro-3 indole phosphate-4) in the dark for development for
20 min. Superfluous water was absorbed and then allowed to dry.
Visual assessment was used to compare dots. The dots can be ana-
lyzed with quantitative analysis software to calculate the amount of
PSA by comparing the dot values from different standard samples.
We calculated the mean value of three repeated square matrixes.
Clinical serum specimens and PSA detection
Serum was obtained from 45 patients aged 49–72 years (mean
61 years) diagnosed with prostate cancer by pathological examina-
tion; 45 patients with prostatic hyperplasia aged 51–70 years (mean
58 years); 15 patients, eight men and seven women, with lung can-
cer (ns6), rectal cancer (ns5) or breast cancer (ns4), aged
40–67 years (mean 53 years); and from 30 patients undergoing
heath examination (18 men and 12 women) aged 40–65 years (mean
age 50 years). All study methods were consistent with the Helsinki
Declaration of 1975 as revised in 1996. Serum specimens were
stored at –808C for future use. Serum was diluted with PBS (1%
BSA) to 1:50, and then 20 mL was used. Testing was performed in
triplicate. The background values obtained by nucleic acid barcode
detection were compared with a standard band. PSA concentrations
)4 ng/mL were considered positive and PSA concentrations
F4 ng/mL were considered negative to determine the specificity
and sensitivity of nucleic acid barcode detection for serum PSA.
The results obtained by nucleic acid barcode detection also were
compared with those obtained with by ELISA (CanAg Diagnostic
AB, Gothenburg, Sweden) and RIA kit (CIS BIO Inc, France).
Paired x2-test was used in the test result analysis.
Statistical analysis
SPSS13 software was used for the statistical analysis of all data.
Qualitative results were expressed as . The x2-test was used to"¯x s
compare quantitative data. Statistical significance was established
as p-0.05. Since data were not normally distributed, Spearman
correlation analysis was used for the results obtained by the nucleic




This method requires two types of probes. The IgG-Au-DNA
probe has a diameter of 30"5 nm with uniform size assessed
by TEM and laser light scattering (9). Gold nanoparticles
may be stored in various types of buffer solutions because
of changes in its stability which helps avoid false positive
tests. The amount of IgG covering the gold nanoparticles can
be detected using Coomassie brilliant blue (G-250) and cal-
culated. The number of IgG molecules covering each IgG-
Au-DNA was 11"3. Thiol-modified oligonucleotides
combined with gold nanoparticles were used as target mol-
ecules. The number of nucleic acid barcode on each probe
is important because detected nucleic acid barcodes were in
direct proportion to measured signal. The number of fluo-
rescin isothiocynate (FITC)-labeled and thiol-modified oli-
gonucleotides on gold nanoparticles replaced by DTT were
calculated with a fluorospectrophotometer. The maximum
dose of oligonucleotide on 1 mL of gold nanoparticles is
about 24.3 mL/mL (165 mg/mL). The number of oligonu-
cleotide on each gold nanoparticle was 138"47.
Characteristics of IgG-M
The cross-linked antibody on the magnetic microsphere com-
bines with antigen, followed by magnetic separation. How-
ever, the affinity interaction (such as antigen-antibody
reaction) between biomolecules possesses steric specificity,
and steric hindrance usually makes the separated biomacro-
molecules not able to bind with ligands resulting in poor
separations efficiency. Therefore, 6-aminocaproic acid is
used as an ‘‘arm’’ molecule to connect with the surface of
microspheres. The ‘‘arm’’ is connected with antibodies by
cross-linked EDC to prepare excellent magnetic microsphere
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Figure 4 Diagram of PSA test standards on Nylon membrane (4 dots in each concentration).
Figure 5 Correlation between nucleic acid barcode assay and
ELISA. Figure 6 Correlation between nucleic acid barcode assay and RIA.
probes. One milligram of magnetic micro-spheres may con-
nect with up to 118 mg of antibodies. Flow cytometry indi-
cated that there were immunoreactive antibodies in 98.3% of
the IgG-M (Figure 2). Big magnetic micro-spheres do not
necessarily have good separation, and may yield false posi-
tive results. IgG-M with 200 nm-mean diameters can achieve
good separation.
Nano-nucleic acid barcode dot detection
PSA was studied due to its important role in prostate cancer
and breast cancer. In patients with prostate cancer, PSA level
was very low following surgery. Also, PSA may be used as
an indicator of tumor recurrence and response to chemo-
therapy (10). In addition, PSA is an important target in
screening for breast cancer. Under normal conditions, serum
PSA is much lower in women than in men. Ultra-sensitive
test methods for PSA are important in screening and diag-
nosis of breast cancer (11). For detection of PSA, the mol-
ecule was captured using a sandwich method with IgG and
IgG-Au-DNA. The compound underwent magnetic separa-
tion in solution. The DNA barcode was released with DTT
and detected directly without the requirement for PCR. Bio-
ssDNA was detected with SAAP. The results were obtained
by visual examination. At the same time, a standard curve
from 1 fg to 1 mg/mL (Figures 3 and 4) was produced, and
PSA concentrations from 100 fg/mL to 1 mg/mL showed
good linear relationship (Rs0.9759). The sensitivity for
analysis obtained from the standard curve was 1 fg/mL. The
semi-quantitative value of the specimen was determined by
visual comparison of specimens with the standard curve. The
color scale of the specimens may also be analyzed with soft-
ware to obtain the amount of PSA when one knows the DNA
barcode in the antigen-antibody complex.
In this method, antigen was detected with two types of
probes using nucleic acid fragment detection. On each IgG-
Au-DNA, protein combines with many oligonucleotides, and
then combines with biotin-streptavidin which greatly increas-
es the sensitivity of the method. The lower limit of PSA in
this method was 100 fg/mL, which is 1000 times more sen-
sitive than ELISA. Compared with immunodetection (1
ng/mL), the method does not require specialized equipment
and safeguards (12). Also, the method is simple and quick.
Sensitivity is increased because of more effective capture
steps and signal background is reduced because the DNA
barcode is detected directly.
Serum PSA detection
Serum specimens from 135 cases (prostate cancer group,
prostatic hyperplasia group, other tumor group and normal
control group) were detected with our method, ELISA and
RIA. PSA )4 ng/mL was considered as positive and PSA
F4 ng/mL was considered negative. x2-test indicated
p)0.05. There were no significant differences in PSA
between the three methods at as0.05.
Since data were not normally distributed, Spearman cor-
relation analysis was used for the PSA results obtained by
nucleic acid barcode dot method, ELISA and RIA (Figures
5 and 6). Results indicated that the coefficient correlations
(r) of nano-nucleic acid barcode dot detection method with
ELISA and RIA were 0.950 (p)0.001) and 0.967
(p)0.001), respectively.
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Conclusions
An ultramicro detection method for protein was established
using nucleic acid barcode as a marker. The number of DNA
barcodes on bioprobes may be adjusted by the size and sur-
face of the gold nanoparticles. The detection limit of this
method is 2–3 orders of magnitude lower than ELISA. This
method does not need special equipment or complex proce-
dures. It only requires probes, magnetic separators and nylon
membrane. Visual assessment or image analysis software can
be used to obtain results with this method. We provide a
technology for detection of ultramicro amounts of protein,
with great potential for different applications.
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